E C G C C

European Conference on Genetics in Cancer Care

21 - 22 January 2027
Lugano - Switzerland



FIRST EUROPEAN CONFERENCE ON GENETICS IN CANCER CARE

BRINGING TOGETHER LEADING EXPERTS IN CANCER GENETICS,
CLINICAL CARE AND RESEARCH
TO ADVANCE PRECISION PREVENTION, EARLY DETECTION AND TREATMENT

Key Topics

- **BAP1** Syndrome – Risk & Prevention
- **Inherited Blood Cancers** – Genetic Risk
- Germline Testing & Precision Therapy
- **Polygenic Risk Score** & Personalised Prevention
- Hereditary GU Cancers – **Surgical Advances**
- Pancreatic Cancer – **Early Detection**
- cfDNA & Emerging Technologies
- **Li-Fraumeni Syndrome** – Precision Variant Interpretation
- **Chemoprevention**
- **AI in Skin Cancer** Syndrome Management

CONNECT • LEARN • COLLABORATE

EXCHANGE KNOWLEDGE, FOSTER COLLABORATION
AND SUPPORT THE NEXT GENERATION OF CANCER GENETICS PROFESSIONALS

APC Society ADVANCED PROSTATE CANCER SOCIETY

Clinical Cancer Genomics Community of Practice · City of Hope ·

Recommended by ESO European School of Oncology

Fondazione per l'Istituto oncologico di ricerca IOR

Swiss Cancer Institute

eoc

Hybrid Conference | In-person & Live Stream
Credit will be requested
LUGANO CONVENTION CENTER

E C G C C
European Conference on Genetics in Cancer Care

WELCOME TO THE FIRST EUROPEAN CONFERENCE ON GENETIC IN CANCER CARE

Dear Colleagues,

It is our great pleasure, on behalf of the Scientific Committee, to invite you to participate in the forthcoming European Conference on Genetics in Cancer Care.
The event will take place at the Palazzo dei Congressi in Lugano on 21–22 January 2027.

In recent years, cancer genetics has become increasingly important in identifying individuals at genetic risk of cancer. The conference will provide an opportunity to improve the care of patients and families with hereditary cancer syndromes.

Our understanding of how to interpret molecular profiling and use germline panel-based testing to guide risk-adapted treatment, as well as targeted therapies such as PARP inhibitors or immunotherapy, has evolved significantly in recent years. Furthermore, identifying germline syndromes is important for discussing strategies such as screening for the early detection and prevention of cancer, and risk reduction programmes involving surgery and chemoprevention.

The aim of this conference is to attract clinical and research experts in the field, to facilitate interaction and discussion of new projects, and to provide enduring mentorship to the next generation of healthcare professionals.

We look forward to meeting you in Lugano in January 2027!

Sincerely,

Manuela Poretti, MD
President of CPTC Network
Swiss Cancer Institute (SCI)
Bern Switzerland

Rossella Graffeo, MD
Clinical Director, Adult Cancer Genetic Outpatient Clinic IOSI
Vice-President of CPTC Network SCI

SCIENTIFIC COMMITTEE:

Francesc Balaguer
Kathleen R. Blazer
Franco Cavalli
Judy E. Garber
Silke Gillessen
Rossella Graffeo
Matteo Lambertini
Aurelius Omlin
Manuela Poretti
Marc Tischkowitz

Thursday, 21 January 2027

12:20-12:30 Welcome and Introduction *R. Graffeo, Oncology Institute of Southern Switzerland EOC/IOSI, Bellinzona, Switzerland*	
12:30- 13:10 Keynote Lecture	
Germline BAP1 and Mesothelioma: Clinical and Pathological Correlation *M. Carbone, University of Hawai'i Cancer Center, Honolulu, USA*	
13:10-14:00 SESSION 1: Exploring New Aspects of Hematological Hereditary Syndromes *Moderator: U. Novak*	
Managing Hereditary Predisposition in Myelodysplastic Syndromes and Acute Myeloid Leukemia: Clinical and Therapeutic Implications *J. Cammenga, Lund University Cancer Centre (LUCC), Lund, SE*	20 min
Clonal Hematopoiesis in Cancer Predisposition Syndrome *U. Novak, Inselspital, University of Bern, CH*	20 min
DISCUSSION and Q/A (10 min)	
14:00- 15:10 SESSION 2: Innovation in Molecular Profiling, Liquid Biopsy and Polygenic Risk Score *Moderator: C .Turnbull*	
Importance of Recognizing Potential Germline Variants on Somatic Tumor Sequencing Panels *C. Turnbull, Institute of Cancer Research, London, UK*	20 min
Liquid biopsy and Early Diagnosis of Hereditary Cancers: Where Are We Now? *R. Kim, Princess Margaret Cancer Centre, University Health Network, Toronto, CA*	20 min
State-of-the-Art Polygenic Risk Scores for Breast, Ovarian, and Prostate Cancer Prediction *A. C. Antoniou, University of Cambridge, UK*	20 min
DISCUSSION and Q/A (10 min)	
COFFEE BREAK 20 min	
15:30- 16:40 SESSION 3: State-of-the-Art in Hereditary Genitourinary Cancers *Moderators: A. Omlin, V. Giri*	
Hereditary Genitourinary Cancers: Germline Genetic Testing, Prevention Strategies *V. Giri, MD, Yale School of Medicine, New Haven, USA*	20 min
Precision and Innovation in Surgery for Hereditary Genitourinary Cancers *A. Gallina, Ospedale Regionale di Lugano EOC/ORL, Lugano, CH*	20 min
Therapeutic Implications of Genetic and Genomic Testing for Genitourinary Cancer Patients *N. Mehra, Radboud University Medical Center, Nijmegen, NL*	20 min
DISCUSSION and Q/A (10 min)	
16:40-17:20 Inspiring and Innovative Lecture	
Recent Advances in Li-Fraumeni Syndrome: Progress in Variant-Specific Risk Interpretation, Evolving surveillance and Emerging Chemoprevention Approaches. *J. E. Garber Dana-Farber Cancer Institute, Boston, USA*	

Friday, 22 January 2027

8:30-9:00 Keynote Lecture	
Pancreatic Cancer Screening: Management Approaches for High-Risk Patients *M. B. Yurgelun, Dana-Farber Cancer Institute, Boston, USA*	
09:00-09:50 SESSION 1: New Aspects of Lynch Syndrome and the Gynecologic Spectrum *Moderators: M.B. Yurgelun, Y Liu*	
Beyond Colorectal Cancer: New Perspectives on Endometrial and Ovarian Cancers in Lynch Syndrome *Y. Liu, Memorial Sloan Kettering Cancer Center, New York, USA*	20 min
Screening and Management of Lynch Syndromes and What's New *M. B. Yurgelun, Dana-Farber Cancer Institute, Boston, USA*	20 min
DISCUSSION and Q/A and workshop (10 min)	
COFFEE BREAK 20 min	
10:10- 12:00 SESSION 2: New Aspects of Hereditary Breast Cancer Syndromes *Moderators: M. Lambertini, R. Graffeo*	
Cancer Risk During Childhood, Adolescence, and Young Adulthood in Carriers of BRCA1 Or BRCA2 Pathogenic Variants *J. Kamihara, Dana-Farber Cancer Institute, Boston, USA*	20 min
Type and Location of BRCA1/2 Variants: Identification, Interpretation, Impact on Risk Assessment and Clinical Outcomes *A. Toss, Azienda Ospedaliero-Universitaria di Modena, University of Modena, IT*	20 min
Risk-Reducing Bilateral Mastectomy and Mortality Outcomes in BRCA1/2 Carriers *V. Galimberti, Istituto Europeo Oncologia (IEO) (Milano), IT*	20 min
Reproductive Challenges for Young Women with Breast Cancer and BRCA Mutations *M. Lambertini, E.O. Ospedali Galliera, Genova, IT*	20 min
DISCUSSION and Q/A (30 min)	
12:00-12:30 Keynote Lecture	
Optimizing PARP Inhibitor Use: Sensitivity, Resistance, and Translational Research in Cancer Patients with Germline BRCA or Other Homologous Recombination Gene *J. Balmaña, Vall d'Hebron Institute of Oncology, Barcelona, SP*	
LUNCH (60 min)	
13:30-15:00 SESSION 3: Innovation in Chemoprevention and Vaccines *Moderators: J. Burn, A. De Censi*	
Chemoprevention for People with Lynch Syndrome *J. Burn, Newcastle University, UK*	20 min
Chemoprevention for Breast Cancer Risk Reduction in Women with Genetic or Familial Predisposition: Where Are We Now? *A. De Censi, Champalimaud Clinical Centre, Lisbon, PT*	20 min
Vaccines for Preventing or Intercepting Breast Cancer in BRCA Mutation Carriers *S. M. Domchek, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA*	20 min
Vaccines for Lynch Syndrome *F. Balaguer, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, SP*	20 min

DISCUSSION and Q/A (10 min)	
15:00-16:00 SESSION 4: Rare Cancer Syndromes and Role of Artificial Intelligence *Moderators: M. Tischkowitz, S. Puig*	
Clinical Insights into Biallelic Germline Variants: What You Need to Know *M. Tischkowitz, University of Cambridge, UK*	20 min
State-of-the-Art Management of Hereditary Skin Cancer Syndromes: The Emerging Role of Artificial Intelligence *S. Puig, Hospital Clínic Barcelona, FCRB-IDBAPS, University of Barcelona, SP*	20 min
DISCUSSION and Q/A and workshop (20 min)	
COFFEE BREAK (20 min)	
16:20-16:50 The Patient Voice: Living with Hereditary Cancer Syndrome	
16:50-17:00 Summary and Closing Remarks *K. Blazer, City-of-Hope, Duarte, USA*	

E C G C C

European Conference on Genetics in Cancer Care

21 - 22 January 2027
Lugano - Switzerland



Contact

IOSI, Bellinzona,
T +41 91 8117560
genetica.oncologica@eoc.ch

For registration:
please scan QR code

Registration fee:
CHF 500

Or website link: medtoday.ch/events/genetics-cancercare-2027

Organization

medtoday Switzerland
c/o PlayToKnow AG
Alte Landstrasse 55
8802 Kilchberg, Switzerland
info@medtoday.ch
medtoday.ch

Sponsor

THANK YOU

LUGANO CONVENTION CENTER (Room1) - Piazza Dell Indipendenza 4 - 6900 Lugano